1.Mammographic findings of breast cancer: Emphasis on the tumor and microcalcifications.
Tae Myon KIM ; Hye Young CHOI ; Seung Yon BAEK ; Su Na CHOI
Journal of the Korean Radiological Society 1993;29(4):833-838
Most of the breast cancer revealed mass and/or microcalcifications on mammography. We analyzed morphologic characteristics of the masses and microcalcifications on mammography which confirmed as breast cancer pathologically. Of all 54 cases, 4 patients (7%) showed microcalcification only, 27 patients (50%), mass only, and the other 23 patients (43%), both microcalcification and mass on the mammography. The margin of the breast mass were ill-defined in 37 cases, well-defined in 8 cases, and well-defined with surrounding infiltration in 5 cases. The morphologic characteristics of the microcalcification were punctate-linear-V shape in 11 patients, punctate-linear shape in 9 patients, and punctate shape in 7 patients.
Breast Neoplasms*
;
Breast*
;
Humans
;
Mammography
2.A Case of Acute Lymphoblastic Leukemia Preceded by Aleukemic Prodrome.
Byoung Su PARK ; Hwang Min KIM ; Baek Keun LIM ; Seok Won PARK ; Young UH ; Mee Yon CHO
Korean Journal of Pediatric Hematology-Oncology 2001;8(1):120-125
Acute lymphoblastic leukemia (ALL), in general, can be diagnosed by detecting blasts in peripheral blood or bone marrow. Some of the cases of ALL do not show typical leukemic features, and only manifest as refractory anemia, thrombocytopenia, myelofibrosis and lymphocytic infiltration into bone marrow. Several months after presentation, they may reveal typical leukemic features and are diagnosed as ALL. This kind of leukemia is called ALL with aleukemic prodrome. Although the incidence of ALL with aleukemic prodrome is 1.5~2.2% of childhood ALL cases, it is rarely reported in Korea. We experienced a 6 month-old female infant who presented with refactory anemia and thrombocytopenia, and two serial of bone marrow examination revealed only myelofibrosis. She subsequently developed ALL 3 months later. We report this case with a brief review of related literatures.
Anemia
;
Anemia, Refractory
;
Bone Marrow
;
Bone Marrow Examination
;
Female
;
Humans
;
Incidence
;
Infant
;
Korea
;
Leukemia
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
;
Primary Myelofibrosis
;
Thrombocytopenia
3.Testing the Biobehavioral Family Model in Understanding the Eating Problems of Adolescent Girls.
Ji Young PARK ; Su Yon BAEK ; Hee Soon KIM ; Jung Ha LIM ; Tae Hyung KIM
Child Health Nursing Research 2013;19(3):228-237
PURPOSE: This study was done to test a hypothesized model, the Biobehavioral Family Model (BBFM), on the relationship of family emotional climate, security of parent-child relationship, depression symptoms and eating problems in adolescent girls, to further understanding of eating problems in this population. METHODS: With a convenience sample of 647 girls, aged 15 to 18, a self-report survey was conducted which included the Korean form of the Eating Attitude Test (EAT-26) to assess eating problems. RESULTS: The estimated results of the structural equation modeling indicated a good fit of data to the hypothesized model proposing that family emotional climate and security of parent-child relationship were associated with the risk of eating problems by way of depression symptoms. That is, negative family emotional climate and insecure parent-child relationship increased the risk of eating problems indirectly by way of depression symptoms. CONCLUSION: The findings are consistent with the BBFM, which suggests a psychobiologic influence of specific family processes on children's stress-sensitive physical disease activity by way of depression symptoms. Therefore, the applicability of the BBFM for understanding adolescent girls' eating problems is supported. The psychobiologic pathways from depression to eating pathology should be addressed in future studies.
Adolescent
;
Aged
;
Climate
;
Depression
;
Eating
;
Feeding and Eating Disorders
;
Humans
;
Parent-Child Relations
4.Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
Seon Ha BAEK ; Hyunsuk KIM ; Jeonghwan LEE ; Dong Ki KIM ; Kook Hwan OH ; Yon Su KIM ; Jin Suk HAN ; Tae Min KIM ; Se Hoon LEE ; Kwon Wook JOO
The Korean Journal of Internal Medicine 2014;29(1):40-48
BACKGROUND/AIMS: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (proteinuria [PU] and renal insufficiency [RI]) and to investigate the relationship between PU and antitumor efficacy. METHODS: We performed a retrospective review of medical records of patients who had received sunitinib for more than 3 months. RESULTS: One hundred and fifty-five patients (mean age, 58.7 +/- 12.6 years) were enrolled, and the mean baseline creatinine level was 1.24 mg/dL. PU developed in 15 of 111 patients, and preexisting PU was aggravated in six of 111 patients. Only one patient developed typical nephrotic syndrome. Following discontinuation of sunitinib, PU was improved in 12 of 17 patients but persisted in five of 17 patients. RI occurred in 12 of 155 patients, and the maximum creatinine level was 3.31 mg/dL. RI improved in two of 12 patients but persisted in 10 of 12 patients. Risk factors for PU were hypertension, dyslipidemia, and chronic kidney disease. Older age was a risk factor for RI. The median progression-free survival was significantly better for patients who showed PU. CONCLUSIONS: The incidence of RAEs associated with sunitinib was lower than those of previous reports. The severity of RAEs was mild to moderate, and partially reversible after cessation of sunitinib. We suggest that blood pressure, urinalysis, and renal function in patients receiving sunitinib should be monitored closely.
Aged
;
Antineoplastic Agents/*adverse effects
;
Carcinoma, Renal Cell/complications/drug therapy/mortality
;
Female
;
Humans
;
Incidence
;
Indoles/*adverse effects
;
Kidney Neoplasms/complications/drug therapy/mortality
;
Male
;
Middle Aged
;
Proteinuria/*chemically induced/epidemiology
;
Pyrroles/*adverse effects
;
Renal Insufficiency/*chemically induced/epidemiology
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Treatment Outcome
5.A Case of Abdominal Actinomycosis Mimicking Colon Carcinoma.
Jeong Eun SHIN ; Sung Ae JUNG ; Seong Eun KIM ; Su Jung BAIK ; Hee Jung OH ; You Kyoung CHO ; Seung Yon BAEK ; Kwon YOO ; Il Hwan MOON
Korean Journal of Gastrointestinal Endoscopy 2003;27(2):84-87
Actinomycosis is a chronic suppurative and granulomatous-disease caused by Actinomycosis israelli. Clinical presentation of the abdominal form of actinomycosis is nonspecific-pain, fever, leukocytosis, increased erythrocyte sedimentation rate, a sensation of abdominal mass and a formation of fistula. In addition, abdominal actinomycosis may mimic a carcinoma, diverticular abscess, inflammatory bowel disease, and tuberculosis. Most of abdominal actinomycosis develops after trauma, appendicitis, diverticulitis or gastrointestinal perforation. We report a case of abdominal actinomycosis preoperatively mimicking as colon carcinoma, which had no predisposing factors.
Abscess
;
Actinomycosis*
;
Appendicitis
;
Blood Sedimentation
;
Causality
;
Colon*
;
Diverticulitis
;
Fever
;
Fistula
;
Inflammatory Bowel Diseases
;
Leukocytosis
;
Sensation
;
Tuberculosis
6.Clinical significance of plasma Antithrombin III in various liver diseases.
Yo Sig SHIN ; Won Hee BAEK ; Su Jin IM ; Gyu Rak CHON ; Young Wook KIM ; Jun Hyoung KIM ; Sang Joon PARK ; Yun Kwon KIM ; So Yon KIM ; Young Jung KIM ; Min Koo CHO ; Gwon Jun LEE
Korean Journal of Medicine 2002;63(4):379-385
BACKGROUND: Antithrombin III (AT-III) produced from hepatocytes and endothelial cells is a coagulation inhibitor. The authors investigated the activity levels of AT-III in patients with liver disease and attempt to elucidate the clinical significance of activity levels of AT-III in relation to various liver disease. METHODS: This study includes 158 patients with liver disease, who visited the National Police Hospital between October 1997 and March 2002. We performed laboratory tests such as LFT, AFP and either abdominal sonography or abdominal CT. At the same time, AT-III activity levels was measured by chromogenic method using ACL 3000 (IL, Lexington, USA). AT-III activity level of 70~120% was regarded as normal. RESULTS: AT-III activity level of liver cirrhosis patients was decreased along with severity of the disease evaluated by Child-Pugh Classification. AT-III activity level of liver cirrhosis patients and hepatocellular carcinoma patients with liver cirrhosis, whose serum AFP were within normal limits, were 50.11+/-2.86% and 75.58+/-6.61%, respectively. The difference between the two groups was statistically significant (p < 0.001). CONCLUSION: Considering the results of the decrease of AT-III activity level in liver cirrhosis patients and the increase in hepatocellular carcinoma patients with liver cirrhosis, further evaluation for the possibility of hepatocellular carcinoma in liver cirrhosis patients without decrease of AT-III level or increase of AFP, may be in need.
Antithrombin III*
;
Carcinoma, Hepatocellular
;
Classification
;
Endothelial Cells
;
Hepatocytes
;
Humans
;
Liver Cirrhosis
;
Liver Diseases*
;
Liver*
;
Plasma*
;
Police
;
Tomography, X-Ray Computed
7.Incident dementia in kidney transplantation recipients: a matched comparative nationwide cohort study in South Korea
Seon Ha BAEK ; Jina PARK ; Sehoon PARK ; Mi-yeon YU ; Ji Eun KIM ; Sang Hyun PARK ; Kyungdo HAN ; Yong Chul KIM ; Dong Ki KIM ; Kwon Wook JOO ; Yon Su KIM ; Hajeong LEE
Kidney Research and Clinical Practice 2023;42(4):519-530
Recent studies have shown that patients with end-stage renal disease (ESRD) are at elevated risk of dementia. However, whether kidney transplantation (KT) lowers the risk for incident dementia remains unclear. Methods: From the Korean National Health Insurance Service database, we identified incident KT recipients aged ≥40 years without any history of dementia between 2007 and 2015. We also established a pair of age-, sex-, and inclusion year-matched control cohorts of patients with incident dialysis-dependent ESRD and members of the general population (GP) without a history of dementia, respectively. Cases of incident all-cause dementia, including Alzheimer disease (AD), vascular dementia (VD), and other kinds of dementia, were obtained from baseline until December 31, 2017. Results: We followed 8,841 KT recipients, dialysis-dependent ESRD patients, and GP individuals for 48,371, 28,649, and 49,149 patient- years, respectively. Their mean age was 52.5 years, and 60.6% were male. Over the observation period, 55/43/19 KT recipients, 230/188/75 dialysis-dependent ESRD patients, and 38/32/14 GP individuals developed all-cause dementia/AD/VD. The risks of incident all-cause dementia, AD, and VD in KT recipients were similar to those in GP (hazard ratio: 0.74 [p = 0.20], 0.74 [p = 0.24], and 0.59 [p = 0.18], respectively) and significantly lower than those in dialysis-dependent ESRD patients (hazard ratio: 0.17 [p < 0.001], 0.16 [p < 0.001], and 0.16 [p < 0.001], respectively). Older age and diabetes mellitus at the time of KT were risk factors for incident all-cause dementia and AD in KT recipients. Conclusion: This is the first study to show a beneficial impact of KT on incident dementia compared to dialysis dependency.
8.Parathyroidectomy versus cinacalcet in the treatment of tertiary hyperparathyroidism after kidney transplantation: a retrospective study
Suyun JUNG ; Hyosang KIM ; Hyunwook KWON ; Sung SHIN ; Young Hoon KIM ; Won Woong KIM ; Tae-Yon SUNG ; Yu-Mi LEE ; Ki-Wook CHUNG ; Su-Kil PARK ; Chung Hee BAEK
Kidney Research and Clinical Practice 2022;41(4):473-481
Hyperparathyroidism is common in patients with chronic kidney disease with reduced renal function and has been observed after kidney transplantation. The optimal treatment for cases in which hyperparathyroidism persists after kidney transplantation has not been determined. Methods: This retrospective study included 83 patients with tertiary hyperparathyroidism who underwent kidney transplantation between 2000 and 2018 at a single tertiary center in Korea. Sixty-four patients underwent parathyroidectomy and 19 patients were treated with cinacalcet following renal transplantation. Biochemical parameters and clinical outcomes were compared between the two groups. Results: Serum calcium and parathyroid hormone (PTH) levels improved in both the parathyroidectomy and cinacalcet groups. One year after treatment, parathyroidectomy resulted in a lower mean serum calcium level than cinacalcet (9.7 ± 0.7 mg/dL vs. 10.5 ± 0.7 mg/dL, p = 0.001). Regarding serum PTH, the parathyroidectomy group showed a significantly lower PTH level than the cinacalcet group at 6 months (129.1 ± 80.3 pg/mL vs. 219.2 ± 92.5 pg/mL, p = 0.002) and 1 year (118.8 ± 75.5 pg/mL vs. 250.6 ± 94.5 pg/ mL, p < 0.001). There was no statistically significant difference in the incidence of kidney transplant rejection, graft failure, cardiovascular events, fracture risk, or bone mineral density changes between the two groups. Conclusion: Parathyroidectomy appears to reduce PTH and calcium levels effectively in tertiary hyperparathyroidism. However, creatinine level and allograft rejection should be monitored closely.
9.Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease
Seon Ha BAEK ; Ran hui CHA ; Shin Wook KANG ; Cheol Whee PARK ; Dae Ryong CHA ; Sung Gyun KIM ; Sun Ae YOON ; Sejoong KIM ; Sang Youb HAN ; Jung Hwan PARK ; Jae Hyun CHANG ; Chun Soo LIM ; Yon Su KIM ; Ki Young NA
The Korean Journal of Internal Medicine 2019;34(4):858-866
BACKGROUND/AIMS:
Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT 00860431).
METHODS:
A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes.
RESULTS:
The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10-μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD.
CONCLUSIONS
Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.
10.Assessing the diagnostic performance of thyroid biopsy with recommendations for appropriate interpretation
Su Min HA ; Jung Hwan BAEK ; Dong Gyu NA ; Chan-Kwon JUNG ; Chong Hyun SUH ; Young Kee SHONG ; Tae Yon SUNG ; Dong Eun SONG ; Jeong Hyun LEE
Ultrasonography 2021;40(2):228-236
Purpose:
The diagnostic performance of thyroid biopsy is influenced by several factors, including differences in the Bethesda categorization for malignancy, the inclusion or exclusion of non-diagnostic results, the definition used for the final diagnosis, and the definition of an inconclusive diagnosis. The purpose of this study was to provide an understanding of the factors influencing the diagnostic performance of thyroid biopsy.
Methods:
We collected data retrospectively between January and December 2013 from a cohort of 6,762 thyroid nodules from 6,493 consecutive patients who underwent biopsy. In total, 4,822 nodules from 4,553 patients were included. We calculated the biopsy sensitivity according to the inclusion of different Bethesda categories in the numerator and the exclusion of non-diagnostic results, as well as the diagnostic accuracy according to different definitions of a benign diagnosis. We obtained the conclusive and inconclusive diagnosis rates.
Results:
The sensitivity increased when more Bethesda categories were included in the numerator and when non-diagnostic results were excluded. When a benign thyroid nodule diagnosis was defined as benign findings on surgical resection, concordant benign results on at least two occasions, or an initial benign biopsy result and follow-up for more than 12 months, the accuracy was higher than when the diagnosis was based on surgical resection alone (68.7% vs. 91.1%). A higher conclusive diagnosis rate was obtained (78.3% vs. 72.8%, P<0.001) when Bethesda categories I and III were considered inconclusive.
Conclusion
Understanding the concepts presented herein is important in order to appropriately interpret the diagnostic performance of thyroid biopsy.